The effect of Monteluca on the symptoms of pyelonephritis in children

Evaluation of Effect of Montelukast on the Symptoms of Pyelonephritis in Children.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190303042893N1

Enrollment

100

Registered

2019-03-17

Start date

2019-03-11

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pyelonephritis. Acute tubulo-interstitial nephritis

Interventions

Intervention 1: Intervention group: In the first group, Montelukast is prescribed at a dose of 5 mg/day. Intervention 2: Control group: In the first group, only the usual treatments of pyelonephritis

Eligibility

Sex/Gender

All

Age

3 Years to 18 Years

Inclusion criteria

Inclusion criteria: Patients with pyelonephritis with clinical symptoms of pyelonephritis and satisfaction with the studyThey are selected as the study group. Satisfaction to participate in the study

Exclusion criteria

Exclusion criteria: Children with underlying illness of kidney, liver and heart.

Design outcomes

Primary

Measure	Time frame
Symptoms of Pyelonephritis. Timepoint: Before taking the drug and 14 days after taking medication. Method of measurement: Registration of symptoms in the checklist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHasan Taher Ahmadi

Arak University of Medical Sciences

HasanTaherAhmadi@gmail.com+98 86 3313 5075

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026